Wholestory

Anthropic's Economic Index and labor-market analyses — measured from actual Claude usage and matched to official labor data, though drawn from one lab's self-selected users — found Claude conversations cover about 33% of the tasks in computer and mathematical occupations (against a 94% theoretical ceiling), topping out at 75% for computer programmers. Anthropic reported no systematic rise in unemployment for the most AI-exposed workers through the period studied, though workers aged 22-25 in exposed jobs saw roughly a 14% lower job-finding rate. About 93% of Claude conversations produced a concrete work artifact, and personal (non-work) use rose from about a third of conversations on weekdays toward half on weekends. Real usage measurement, with its motivated-source provenance labeled.

The FDA's AI-Enabled Medical Device List reached 1,524 authorized AI/ML-enabled devices, of which 1,164 (about 76%) are in radiology. The count has climbed from 64 in 2020 and 950 as of August 2024 — the clearest regulator-administered measure of AI moving into frontline clinical deployment, and the deployment curve this page's instrument tracks. Growth is real but heavily concentrated in imaging.

The Census Bureau's Business Trends and Outlook Survey found overall U.S. business AI use hovering between 17% and 20% (a national rate near 19.8% as of the collection period ending May 3, 2026), the clearest population-scale measurement of enterprise adoption. The gap is by firm size: 37% of firms with at least 250 employees reported using AI versus under 20% of the smallest firms, and use ran highest in the Information (39.7%) and Finance and Insurance (33.9%) sectors. A second AI supplement launched in November 2025 broadened the survey to 15 business functions. Measured adoption is broad and climbing but still a minority of firms — and concentrated among the largest.

A Federal Reserve analysis (Allen, FEDS Notes) laid out why headline AI-adoption rates diverge so widely: the Census Bureau's business survey put firm adoption at about 18% at year-end 2025; a real-time population survey found about 41% of workers using generative AI; and a survey of senior leaders estimated 78% of the labor force works at a firm that has adopted AI. The Fed attributed the spread mainly to what each survey samples (firms vs individuals vs labor-force-weighted) and how it frames the question, and flagged a Census methodological change in late 2025 that breaks the earlier trend. The essential caveat for reading every number on this page: adoption is real and rising, but its 'level' depends entirely on the unit of measurement.

The MASAI trial — the first randomized controlled trial of AI-supported mammography screening, following more than 100,000 women in Sweden — published final results in The Lancet. AI-supported screening detected 81% of cancers at screening versus 74% for standard double-reading, cut the interval-cancer rate (cancers found between screens) by about 12% (1.55 vs 1.76 per 1,000), and left the false-positive rate essentially unchanged, while an earlier analysis found it reduced radiologist reading workload by about 44%. Investigators were deliberately cautious: lead author Kristina Lång (Lund University) called it the first RCT evidence that AI is safe to use in screening, and first author Jessie Gommers (Radboud) noted the results do not yet prove AI reduces the advanced cancers that drive mortality. Peer-reviewed, gold-standard clinical evidence — the counterpoint to the Watson precedent.

S&P Global Market Intelligence (451 Research) found the share of companies abandoning most of their AI initiatives had risen to 42%, up from 17% a year earlier, and that 46% reported no single enterprise objective had produced strong positive impact — even as about 60% of AI investors had implemented generative AI in production. The figures come from a survey of 1,006 respondents and measure reported behavior and sentiment, not audited outcomes; the most-cited obstacles were data confidentiality, cost and accuracy.

MIT's NANDA initiative reported in 'The GenAI Divide: State of AI in Business 2025' that about 95% of enterprise generative-AI pilots it studied had produced no measurable profit-and-loss impact, with roughly 5% delivering real value. Tools bought from specialized vendors succeeded about twice as often as those built in-house (about 67% vs 33%), and workforce disruption showed up mainly as unfilled vacancies in customer-support and administrative roles rather than mass layoffs. The finding is a report drawing on 150 leader interviews, a 350-person survey and 300 public deployments — not audited financials — but it is the most-cited reality check on the enterprise-adoption story, and it sits against the U.S. Census Bureau's measured finding that roughly 20% of firms use AI at all: many companies are trying AI; few have yet shown it pays.

In a randomized controlled trial, METR had 16 experienced open-source developers complete 246 real issues on mature codebases they maintain, with and without early-2025 AI tools (Cursor Pro with Claude 3.5/3.7). The developers were 19% slower with AI — even though they had expected a 24% speedup and, afterward, believed AI had sped them up by about 20%. The result sits directly against the 2023 GitHub Copilot trial, which measured a 55.8% speedup: the two randomized experiments reach opposite-signed results because they test different tasks and populations — a narrow greenfield task with mixed-experience recruits versus expert maintainers on complex real code. The gap between measured and perceived productivity is itself the finding.

Klarna began rehiring human customer-service staff after having said AI was doing the work of hundreds of agents, in what several outlets framed as a reversal. Klarna disputed that framing: it says it continues to invest heavily in AI, that its assistant handles the work of more than 800 full-time roles, and that the new hiring is a small quality pilot rather than a retreat. CEO Sebastian Siemiatkowski said an overemphasis on cost-cutting — not AI itself — had hurt service quality. Both the reversal framing and the company's rebuttal are recorded so the contested claim stays auditable.

The Royal Swedish Academy of Sciences awarded the 2024 Nobel Prize in Chemistry half to Demis Hassabis and John Jumper of Google DeepMind 'for protein structure prediction' with AlphaFold, and half to David Baker 'for computational protein design.' Committee chair Heiner Linke said the recognized discoveries 'hold enormous potential.' By the announcement, AlphaFold2 had been used by more than two million people in 190 countries. It is the first Nobel Prize to recognize a modern deep-learning system's direct scientific contribution — the strongest possible independent verdict that AI has produced real science.

Google DeepMind's AlphaProof and AlphaGeometry 2 together solved four of the six 2024 International Mathematical Olympiad problems for 28 of 42 points — the silver-medal threshold, one point below gold. The solutions were graded by the competition's own markers, including Fields Medalist Timothy Gowers, making it an independently verified demonstration of AI mathematical reasoning rather than a self-reported score.

Google DeepMind and Isomorphic Labs published AlphaFold 3 in Nature, a diffusion-based model that predicts the joint structure of proteins together with nucleic acids, small-molecule ligands and ions — the interactions that matter for drug discovery, not just isolated protein shapes. A peer-reviewed step from a scientific result toward a deployable tool.

The Census Bureau released the first AI supplement to its Business Trends and Outlook Survey, sampling roughly 1.2 million businesses on whether they actually use AI to produce goods and services. It established the country's first population-scale, measured (rather than self-selected or intention-based) record of enterprise AI adoption — the backbone against which vendor and survey claims can be checked.

In Nature, Google DeepMind's GNoME predicted about 2.2 million new inorganic crystals, roughly 380,000 of them stable enough to be candidates for synthesis. Crucially the result was partly validated outside DeepMind: a companion literature review found external laboratories had already independently synthesized 736 of the predicted structures, and Lawrence Berkeley National Laboratory's autonomous 'A-Lab' made more than 41 using GNoME's stability predictions — independent corroboration of a vendor claim.

In a paper in Science, Google DeepMind's GraphCast produced 10-day global weather forecasts in under a minute on a single machine and outperformed the European Centre's gold-standard HRES system on more than 90% of 1,380 verification targets. A peer-reviewed demonstration that AI can rival established physical-simulation methods on an operational scientific task.

A field experiment with more than 750 Boston Consulting Group consultants using GPT-4 (Dell'Acqua, Lakhani et al., later peer-reviewed in Organization Science) found sharply divided results. On creative product-innovation tasks 'inside the frontier,' AI users performed about 40% better, with the biggest gains for the lowest-baseline performers. But on a business-problem-solving task designed to lie just 'outside the frontier' — where the AI was confidently wrong — consultants using GPT-4 were about 23% less likely to reach the correct answer than those without it. The AI's uniform output also cut the diversity of ideas across the group by roughly 41%.

Insilico Medicine began Phase II trials of INS018_055 (later rentosertib), an idiopathic-pulmonary-fibrosis candidate the company says is the first drug both discovered and designed using generative AI — a claim that is a sponsor characterization, not an independent or peer-reviewed finding, and the drug is not approved. Co-CEO Feng Ren called reaching Phase II a validation of AI-driven drug discovery. Recorded here as a documented milestone in AI's medical pipeline, with its provenance labeled.

A field study of 5,179 customer-support agents (Brynjolfsson, Li and Raymond, published through the NBER) found that access to a generative-AI conversation assistant raised issues resolved per hour by an average of 14% — and by about 34% for the least-experienced agents, while barely helping the most experienced. AI assistance also improved customer sentiment, agent retention and how quickly new hires reached proficiency. It is the landmark early evidence that measured workplace value from AI is real but unevenly distributed, concentrated among lower-skilled workers.

In a randomized controlled experiment, software developers given GitHub Copilot completed a self-contained task (writing an HTTP server in JavaScript) 55.8% faster than a control group. The result is one of the earliest clean measurements of AI coding assistance — but on a narrow, greenfield task, a caveat that later real-world studies would sharpen (see the 2025 METR trial).

Roughly two months after its late-November 2022 launch, ChatGPT was estimated to have reached 100 million users — described at the time as the fastest-growing consumer application in history. The 100-million figure is a third-party estimate (Similarweb, cited by UBS), not an OpenAI-reported metric; it marks the moment consumer AI adoption became a mass phenomenon.

The AlphaFold team uploaded predicted structures for nearly all catalogued proteins — about 200 million — to the open AlphaFold Protein Structure Database, turning a research result into shared scientific infrastructure. By the time of the 2024 Nobel announcement the database and model had been used by more than two million people from 190 countries, one of the clearest cases of measured real-world scientific adoption.

DeepMind's AlphaFold2 won the 14th Critical Assessment of Structure Prediction (CASP14) with a median global-distance score around 92.4 out of 100 — accuracy competitive with experimental methods for many proteins. Independent CASP assessors described the roughly 50-year 'protein-folding problem' as essentially solved for a large class of proteins. This is the origin of the modern evidence that AI can produce real, independently graded scientific results.

MD Anderson Cancer Center shelved its IBM Watson 'Oncology Expert Advisor' in 2016 after spending a reported $62 million and never deploying it in clinical care. Independent studies later found Watson for Oncology's recommendations matched expert panels unevenly by geography (about 73% concordance in India, 49% in South Korea), and IEEE Spectrum counted nearly 50 Watson Health partnership announcements since 2011, many of which produced no tools in use. It is the reference case for AI hype outrunning delivery in medicine — the failure the rest of this record is measured against.